Drug
Erenumab
Erenumab: highest development phase Post-Market, developed by Amgen. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Erenumab NCT04252742 | Post-Market | Migraine |
| Erenumab NCT01688739 | Phase 1 | Migraine |
Latest
No recent events.
Follow Erenumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.